

**Request for Prior Authorization  
 PCSK9 INHIBITORS**

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB
Patient address		
Provider NPI	Prescriber name	Phone
Prescriber address		Fax
Pharmacy name	Address	Phone
<b>Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.</b>		
Pharmacy NPI	Pharmacy fax	NDC

**Prior authorization is required for PCSK9 Inhibitors. Payment for non-preferred PCSK9 Inhibitors will be authorized only for cases in which there is documentation of a previous trial and therapy failure with a preferred agent, when available for the submitted diagnosis. Payment will be considered under the following conditions: 1) Patient is 18 years of age or older (or, for Homozygous Familial Hypercholesterolemia (HoFH), patient is 13 years of age or older); and 2) Current use of a statin and documentation of adherence to prescribed lipid lowering medications for the previous 90 days is provided (further defined below, by diagnosis); and 3) Is to be prescribed as an adjunct to a low fat diet; and 4) A baseline and current lipid profile is provided. Baseline lipid profile is defined as a lipid profile obtained prior to pharmacologic therapy; and 5) Documentation patient has been counseled on importance of abstinence from tobacco and, if a current smoker, be encouraged to enroll in a smoking cessation program; and 6) Is prescribed by a lipidologist, cardiologist, or endocrinologist. 7) The 72-hour emergency supply rule does not apply to PCSK9 Inhibitors. 8) Prescriber and dispensing pharmacy will educate the patient on proper storage and administration. Improperly stored medications will not be replaced. 9) Lost or stolen medication replacement requests will not be authorized. 10) Goal is defined as a 50% reduction in untreated baseline LDL-C. 11) Is prescribed for one of the following diagnoses: Heterozygous Familial Hypercholesterolemia (HeFH), Clinical Atherosclerotic Cardiovascular Disease (ASCVD), or HoFH. The required trials (excluding the statin trial) may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.**

**Quantity Limits:**

Praluent/Repatha for HeFH or ASCVD: One syringe/pen/autoinjector per fill (requires refill every 14 days)  
 Repatha for HoFH only: One three-pack per month

**Initial Requests (please see below for renewal requests):**

**HeFH or ASCVD Drug and Dose Requested:**

- Praluent 75mg every 2 weeks for 8 weeks (4 doses)
- Repatha 140mg every 2 weeks for 8 weeks (4 doses)

**HoFH Drug and Dose Requested:**

- Repatha 420mg (3x140mg autoinjectors) every month for 3 months

**Is patient on a low fat diet:**     Yes     No

**Has patient experienced ≥ 50% reduction in untreated baseline LDL-C with current therapies?**

- Yes     No

**Attach baseline (prior to pharmacologic therapy) and current lipid profiles.**

**Request for Prior Authorization**  
**PCSK9 INHIBITORS - continued**  
 (PLEASE PRINT – ACCURACY IS IMPORTANT)

**Statin to be used as adjunct to PCSK9 inhibitor:** \_\_\_\_\_ **Dose:** \_\_\_\_\_

**Has patient been counseled on importance of abstinence from tobacco?**  Yes  No

**Is patient a current smoker or tobacco user:**  Yes  No

If yes, has patient been encouraged to enroll in smoking cessation program?  Yes  No

**Prescriber Specialty:**  Lipidologist  Cardiologist  Endocrinologist  Other: \_\_\_\_\_

**Prescriber and dispensing pharmacy will educate patient on proper storage and administration?**

Yes  No

**Heterozygous Familial Hypercholesterolemia (HeFH)**

- 1) Total cholesterol > 290mg/dL or LDL-C > 190mg.dL; *and*
  - a) Presence of tendon xanthomas; *or*
  - b) In first or second degree relative, one of the following: documented tendon xanthomas, MI at age ≤ 60 years, or total cholesterol > 290mg/dL; *or*
  - c) Confirmation of diagnosis by gene or receptor testing (attach results); *and*
- 2) Unable to reach goal LDL-C with a minimum of two separate, chemically distinct statin trials used in combination with other lipid lowering medications.

Trials are defined as: concurrent use of a maximally tolerated dose of a statin (including atorvastatin and rosuvastatin), plus ezetimibe (Zetia) 10mg daily, plus cholestyramine daily.

**Total cholesterol:** \_\_\_\_\_ **Date obtained:** \_\_\_\_\_

**LDL-C:** \_\_\_\_\_ **Date obtained:** \_\_\_\_\_

**Presence of tendon xanthomas:**  Yes  No

**Any of the following present in first degree relative:**

Documented tendon xanthomas  MI at age ≤ 60 years  Total cholesterol > 290mg/dL

**Diagnosis confirmed by gene or receptor testing?**  Yes (attach results)  No

**Statin 1 trial:**

Dose: \_\_\_\_\_ Trial dates: \_\_\_\_\_

Failure reason: \_\_\_\_\_

**Statin 2 trial:**

Dose: \_\_\_\_\_ Trial dates: \_\_\_\_\_

Failure reason: \_\_\_\_\_

**Plus concurrent ezetimibe (Zetia) trial:**

Dose: \_\_\_\_\_ Trial dates: \_\_\_\_\_

Failure reason: \_\_\_\_\_

**Plus concurrent cholestyramine trial:**

Drug name & dose: \_\_\_\_\_ Trial dates: \_\_\_\_\_

Failure reason: \_\_\_\_\_

**Medical or contraindication reason to override trial requirements:** \_\_\_\_\_

**Request for Prior Authorization**  
**PCSK9 INHIBITORS - continued**  
 (PLEASE PRINT – ACCURACY IS IMPORTANT)

**Clinical Atherosclerotic Cardiovascular Disease (ASCVD)**

- 1) History of MI, angina, coronary or other arterial revascularization, stroke, TIA, or PVD of atherosclerotic origin; *and*
- 2) Unable to reach goal LDL-C with a minimum of two separate, chemically distinct statin trials used in combination with other lipid lowering medications.

Trials are defined as: concurrent use of a maximally tolerated dose of a statin (including atorvastatin and rosuvastatin), plus ezetimibe (Zetia) 10mg daily, plus cholestyramine daily.

**History of any of the following:**     MI             Angina  
 Coronary or other arterial revascularization     Stroke             TIA             PVD of atherosclerotic origin

**Statin 1 trial:**

Dose: \_\_\_\_\_ Trial dates: \_\_\_\_\_

Failure reason: \_\_\_\_\_

**Statin 2 trial:**

Dose: \_\_\_\_\_ Trial dates: \_\_\_\_\_

Failure reason: \_\_\_\_\_

**Plus concurrent ezetimibe (Zetia) trial:**

Dose: \_\_\_\_\_ Trial dates: \_\_\_\_\_

Failure reason: \_\_\_\_\_

**Plus concurrent cholestyramine trial:**

Drug name & dose: \_\_\_\_\_ Trial dates: \_\_\_\_\_

Failure reason: \_\_\_\_\_

**Medical or contraindication reason to override trial requirements:** \_\_\_\_\_

**Homozygous Familial Hypercholesterolemia (HoFH) – Repatha only**

- 1) Total cholesterol and LDL-C > 600mg/dL and triglycerides within reference range; or
- 2) Confirmation of diagnosis by gene or receptor testing (attach results); and 3) Unable to reach goal LDL-C with a minimum of two separate, chemically distinct statin trials used in combination with other lipid lowering medications.

Trials are defined as: concurrent use of a maximally tolerated dose of a statin (including atorvastatin and rosuvastatin), plus ezetimibe (Zetia) 10mg daily, plus cholestyramine daily.

**Total cholesterol:** \_\_\_\_\_ Date obtained: \_\_\_\_\_

**LDL-C:** \_\_\_\_\_ Date obtained: \_\_\_\_\_

**Triglycerides within reference range?**     Yes             No (attach results)

**Diagnosis confirmed by gene or receptor testing?**     Yes (attach results)     No

**Statin 1 trial:**

Dose: \_\_\_\_\_ Trial dates: \_\_\_\_\_

Failure reason: \_\_\_\_\_

**Statin 2 trial:**

Dose: \_\_\_\_\_ Trial dates: \_\_\_\_\_

Failure reason: \_\_\_\_\_

**Request for Prior Authorization**

**PCSK9 INHIBITORS - continued**

(PLEASE PRINT – ACCURACY IS IMPORTANT)

**Plus concurrent ezetimibe (Zetia) trial:**

Dose: \_\_\_\_\_ Trial dates: \_\_\_\_\_

Failure reason: \_\_\_\_\_

**Plus concurrent cholestyramine trial:**

Drug name & dose: \_\_\_\_\_ Trial dates: \_\_\_\_\_

Failure reason: \_\_\_\_\_

**Medical or contraindication reason to override trial requirements:** \_\_\_\_\_

**Renewal Requests:**

**HeFH or ASCVD (Praluent or Repatha)**

**Lipid profile required at week 8, week 24, and every 6 months thereafter (attach results).**

Yes Most recent date obtained: \_\_\_\_\_ LDL-C: \_\_\_\_\_  No

**Praluent:**

- LDL-C at goal – continue therapy at 75mg every 2 weeks for 24 weeks
- LDL-C not at goal – increase dose to 150mg every 2 weeks for 8 weeks (4 doses) and repeat LDL-C in 8 weeks
  - o If repeat LDL-C at goal – continue therapy at 150mg every 2 weeks for 24 weeks
  - o If repeat LDL-C not at goal – discontinue treatment

**Repatha:**

- LDL-C at goal – continue therapy at 140mg every 2 weeks for 24 weeks
- LDL-C not at goal – discontinue treatment

**Patient continues therapy with a maximally tolerated statin dose and remains at goal?**  Yes  No

Current Statin: Drug name: \_\_\_\_\_ Dose: \_\_\_\_\_

**Patient has continued compliance with a low fat diet?**  Yes  No

**HoFH (Repatha only)**

**Lipid profile required after 3 months (third dose) and every 6 months thereafter (attach results).**

Yes Most recent date obtained: \_\_\_\_\_ LDL-C: \_\_\_\_\_  No

- LDL-C at goal – continue therapy at 420mg every month for 6 months
- LDL-C not at goal – discontinue treatment

**Patient continues therapy with a maximally tolerated statin dose and remains at goal?**  Yes  No

**Patient has continued compliance with a low fat diet?**  Yes  No

***Attach lab results and other documentation as necessary.***

Prescriber signature (Must match prescriber listed above.)	Date of submission
--	--------------------

**IMPORTANT NOTE:** In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.